7 min de lectura
Human Factors Is Now an Evidence Strategy Decision
Human factors engineering has long been integral to designing medical devices that can be used safely and effectively. In 2026, however, FDA sharpened an important regulatory question for manufacturers: not simply whether human factors activities have been performed, but what human factors information should be included in a marketing submission and why.
FDA issued its final Content of Human Factors Information in Medical Device Marketing Submissions guidance in May 2026. It establishes a risk-based framework for determining the human factors information recommended in 510(k)s, De Novo requests, Premarket Approval Applications (PMAs), and Humanitarian Device Exemption (HDE) applications. FDA implemented the new recommendations on August 1, 2026.
For manufacturers navigating the FDA human factors guidance August 1 2026 implementation, the strategic shift is significant: the objective is not more human factors documentation by default, but evidence proportionate to the device’s use-related risk and submission context.
What Changed in FDA’s 2026 Human Factors Guidance?
The FDA human factors guidance for medical devices introduces three Human Factors (HF) Submission Categories that determine the recommended level of HFE/UE information in a medical device marketing submission.
The submission-content guidance works alongside FDA’s Applying Human Factors and Usability Engineering to Medical Devices guidance. The latter addresses how manufacturers should apply human factors engineering and usability engineering throughout device development, while the new submission guidance focuses on what human factors information FDA recommends seeing in the marketing submission.
This distinction matters because conducting human factors engineering and deciding what human factors evidence to submit are related, but they are not identical decisions.
Combination Product Human Factors: FDA Scope Note
The 2026 submission-content guidance applies to medical devices reviewed by CDRH but specifically states that combination products are not addressed because they may involve additional risks and considerations.
For combination product human factors, FDA provides separate guidance on the application of human factors engineering principles for combination products, addressing considerations specific to products combining device, drug, or biological product constituent parts.
HF Submission Category 1 vs 2 vs 3: Examples and Evidence Expectations
FDA’s human factors submission categories progressively increase the recommended level of human factors information according to the device, its use-related risk, and the outcome of the risk-based decision framework.
HF Submission Category 1 generally applies to modified devices when the modification does not affect relevant human factors considerations. FDA recommends a conclusion and high-level summary explaining why the change does not affect factors such as the user interface, intended users, uses, use environments, training, or labeling.
HF Submission Category 2 requires additional rationale. This may include explaining why a new device has no critical tasks, why a modification introduces no new or affected critical tasks, or why new human factors validation data do not need to be submitted.
HF Submission Category 3 calls for a comprehensive HFE/UE report that includes human factors validation testing and supporting human factors evidence.
These HF Submission Category 1 vs 2 vs 3 examples illustrate an important principle: a lower category should not be interpreted as “no human factors work required.” It means the manufacturer should be able to support why a more extensive evidence package is unnecessary.
Use-Related Risk Analysis (URRA) and Critical Tasks in FDA Human Factors
The Use-Related Risk Analysis (URRA) is central to the risk-based framework FDA applies to human factors submission decisions. It connects potential use errors, hazardous situations, harm, critical tasks, and risk-control measures.
A critical task, in FDA human factors terminology, is a user task that, if performed incorrectly or not performed at all, would or could cause serious harm to the patient or user, including compromised medical care.
For new devices, the URRA helps determine whether critical tasks exist. For modified devices, it helps determine whether new critical tasks have been introduced or existing critical tasks are affected.
When evaluating modified devices, manufacturers should also consider the cumulative impact of multiple changes rather than evaluating each change only in isolation.
The strategic implication is that the URRA should not be treated merely as supporting documentation. It provides traceable regulatory logic connecting use-related risk, design controls, validation strategy, and the level of human factors evidence presented to FDA.
Does Every Medical Device Need Human Factors Validation Testing?
No. The presence of human factors considerations does not automatically mean that new human factors validation testing data must be submitted for every device.
The FDA human factors guidance 2026 uses a risk-based approach to determine what human factors information should accompany a marketing submission. The assessment considers critical tasks, user-interface history and complexity, known use-related problems, existing risk controls, and the characteristics of the device or modification.
Depending on that assessment, a documented rationale may be appropriate instead of submitting new human factors validation data.
This changes the submission-planning question from simply:
“Do we need an HF study?” to: “What human factors evidence is necessary to support the conclusion for this device and submission?”
That distinction can help manufacturers avoid both insufficient evidence and unnecessary testing.
Human Factors Guidance for Modified 510(k) Devices: What Changes Matter?
Modified devices are particularly important under FDA’s framework because human factors assessment extends beyond obvious physical design changes.
Under the human factors guidance for modified 510(k) devices, manufacturers should consider changes to the user interface, intended users, intended uses, use environments, training, and labeling. When multiple modifications are involved, their cumulative impact on critical tasks should also be evaluated.
For a 510(k) modified device, human factors assessment should therefore look beyond whether the device appears or functions differently. A software workflow change, new user population, altered training approach, revised labeling, or change in use environment may affect how users interact with the device and therefore alter use-related risk.
Importantly, the FDA human factors guidance addresses the information that should be included in a marketing submission. It is not intended to determine whether a new marketing submission is required for a particular device modification.
Human factors assessment should consequently be integrated with design and regulatory change control rather than triggered only when a major physical interface change occurs.
FDA Decision Point D: Human Factors Validation Evidence
An important part of FDA’s risk-based framework is Decision Point D.
Where critical tasks are present for a new device, or new or impacted critical tasks are identified for a modified device, FDA Decision Point D human factors analysis considers whether human factors validation test data should be submitted.
FDA identifies three important considerations:
- user-interface history of use for the intended use, users, and use environment;
- device user-interface complexity; and
- adequacy of existing risk-control measures.
These considerations reinforce that human factors validation evidence should be driven by use-related risk and device characteristics rather than by a one-size-fits-all submission expectation.
Three Questions for a Strong Human Factors Evidence Strategy
FDA’s 2026 framework can be translated into three connected questions that manufacturers should address early in device development or change assessment.
What can go wrong during use? This is the role of the URRA, known-use-problem assessment, and critical-task identification.
What has changed or needs to be controlled? This includes the user interface, users, uses, environments, labeling, training, and effectiveness of risk-control measures.
What evidence does FDA need to see? The answers to the first two questions inform the HF Submission Category and whether a high-level conclusion, documented rationale, or comprehensive HFE/UE report with validation testing is appropriate.
The key insight is that use-related risk, design or change assessment, and submission evidence should not be treated as separate regulatory exercises. They form one evidence chain.
From Human Factors Testing to Human Factors Submission Readiness
Human factors submission readiness should begin before validation testing.
Manufacturers that identify intended users, use environments, known use problems, critical tasks, and risk controls early can better align formative evaluations, device development, validation, and regulatory documentation.
This creates a traceable pathway:
Use-related risk → Design decisions → Risk controls → Validation strategy → Residual risk → Submission content
That traceability is particularly important because the FDA human factors guidance 2026 is fundamentally about proportionality. The strongest submission is not necessarily the one containing the most human factors material; it is the one in which the amount and type of evidence are clearly justified by the device’s use-related risk.
Conclusion: From HF Compliance to Evidence Proportionality
FDA’s 2026 human factors guidance reframes submission planning around the relationship between risk and evidence. Critical tasks, URRA findings, interface complexity, device modifications, risk controls, and validation strategy collectively determine what human factors information should support a marketing submission.
For manufacturers, the central takeaway is clear: human factors should be planned as an evidence strategy, not as a late-stage usability test. Determining the likely HF Submission Category early can help align device development, risk management, change control, validation, and regulatory submission planning.
Freyr supports medical device manufacturers across human factors and usability engineering, U.S. regulatory strategy, risk management, technical documentation, and medical device marketing submissions. By aligning human factors activities with product development and regulatory planning, manufacturers can establish a more traceable evidence pathway from use-related risk assessment through validation and submission.
For medical device manufacturers looking to strengthen human factors engineering, usability testing, or FDA submission readiness, speak to a Freyr expert to assess your human factors strategy and evidence requirements.
